| Followers | 177 |
| Posts | 24415 |
| Boards Moderated | 12 |
| Alias Born | 04/03/2002 |
Monday, January 09, 2023 12:00:04 PM
$CURR is looking good for 2023. The upcoming Q4 financial report is projected to deliver continued revenue growth and improvements based on the successful marketing of the company's wellness and anti-aging product lines.
https://finance.yahoo.com/news/cure-pharmaceutical-reports-third-quarter-110000414.html
From the Q3 results:
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
https://finance.yahoo.com/news/cure-pharmaceutical-reports-third-quarter-110000414.html
From the Q3 results:
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
